Strona 3 - Najlepsi lekarze do leczenia nowotworu kości – TOP 86 lekarzy

Doc. dr Nail Paksoy specjalizuje się w leczeniu nowotworów kości w szpitalu Medipol Bahçelievler oraz prowadzi szeroko zakrojone badania nad metodami leczenia mięsaków.

• Posiada certyfikat ESMO w dziedzinie onkologii klinicznej, co zapewnia stosowanie najnowocześniejszych protokołów leczenia
• Opublikował liczne prace badawcze na temat mięsakokostniaków oraz wyników stosowania chemioterapii w wysokich dawkach
• Uczestniczył w międzynarodowych badaniach klinicznych nad terapiami zaawansowanych guzów litych
• Odbył staż specjalizacyjny w Instytucie Onkologii Uniwersytetu Stambulskiego

Dr Alemdar koncentruje się na leczeniu nowotworów kości i odbył specjalistyczne szkolenie w zakresie onkologii klinicznej na Uniwersytecie Akdeniz.

• Posiada ponad 18-letnie doświadczenie medyczne ze szczególnym uwzględnieniem onkologii
• Ukończył zaawansowane szkolenie na Wydziale Lekarskim Uniwersytetu Akdeniz
• Pracuje w kompleksie szpitalnym Medical Park Antalya, wiodącej placówce medycznej
• Jest członkiem Tureckiego Towarzystwa Onkologii Klinicznej

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Dr Ozden specjalizuje się w onkologii klinicznej, a swoje szerokie doświadczenie zdobywał na Uniwersytecie Stambulskim oraz Uniwersytecie Kocaeli.

• Ukończył podspecjalizację z onkologii klinicznej na Uniwersytecie Kocaeli
• Posiada ponad 16-letnie doświadczenie w zakresie chorób wewnętrznych i onkologii
• Praktykował w Państwowym Szpitalu w Şırnak oraz w Prywatnym Szpitalu Safa w Bağcılar

Przeprowadził ponad 3000 operacji nowotworów kręgosłupa – prof. Boriani opracował system WBB, stosowany obecnie na całym świecie do klasyfikacji stopnia zaawansowania guzów kręgosłupa.

• Dyrektor ds. chirurgii nowotworów kręgosłupa w IRCCS Istituto Ortopedico Galeazzi
• Wynalazł system z włókna węglowego do rekonstrukcji po usunięciu nowotworu
• Autor ponad 430 artykułów naukowych z zakresu onkologii kręgosłupa
• Członek honorowy wielu międzynarodowych towarzystw zajmujących się schorzeniami kręgosłupa

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Dr. Mohamed Mahmoud Abdelhakim is Head of Radiation Oncology at Shefa al Orman Hospital, Luxor. He is Professor of Radiation Oncology at the National Cancer Institute, Cairo University. He previously served as Associate Professor (2015–2020), Lecturer (2010–2015), Assistant Lecturer (2003–2009), and Resident (2000–2003). He also worked as a Specialist at Gharbia Cancer Society.

He treats inpatients and outpatients with breast, soft tissue sarcoma, lymphoma, gynecologic, gastrointestinal, genitourinary, and CNS tumors. His skills include image-guided brachytherapy, IMRT, VMAT, SRS, and SBRT. He performs conventional and CT-based planning and 3D-CRT. He works with cobalt and linear accelerators and electron beam therapy. He provides HDR and LDR intracavitary and interstitial brachytherapy. He also performs stereotactic radiotherapy, total body irradiation, and total skin irradiation.

Member: Egyptian Cancer Society, ESTRO, ESMO.

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dr. Eytan Aharon Ben‑Ami, MD, is a Senior Physician in the Sarcoma and Bone Oncology Service at Sheba Medical Center. He heads the Oncology Division and the Early-Phase Clinical Trials Unit. He founded the Sheba Clinical Research Organization. He is an academic affiliate at Tel Aviv University.

He specializes in sarcomas and primary bone tumors, including soft tissue sarcoma, liposarcoma, leiomyosarcoma, and osteosarcoma. He leads Phase I trials in targeted therapy and immunotherapy. He designs personalized treatment plans for rare cancers. He also develops patient-centered programs, including pilots in advanced immunotherapy delivery.

He completed a fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute/Harvard Cancer Center. He has authored more than 40 publications on early detection, molecular and viral mechanisms, and new cancer therapies.

Ortopeda, Onkolog, Specjalista w leczeniu mięsaków kości

Chirurg ortopedyczny

Profesor Ofluoglu odbył staż w zakresie nowotworów kości i tkanek miękkich w czołowych amerykańskich ośrodkach, takich jak University of Pennsylvania i University of California.

• Specjalizuje się konkretnie w chirurgii ortopedyczno-onkologicznej u dzieci i dorosłych.
• Posiada około 30-letnie doświadczenie w chirurgii ortopedycznej.
• Przeszedł szkolenie w zakresie metody Ilizarowa stosowanej w złożonych rekonstrukcjach kości w Rosji.
• Jest autorem ponad 50 publikacji medycznych oraz członkiem międzynarodowych towarzystw onkologicznych.

Dr Meushar jest ordynatorem oddziału specjalizującego się w leczeniu nowotworów kości w Centrum Medycznym Rambam.

• Specjalizuje się wyłącznie w leczeniu nowotworów kości
• Kieruje wyspecjalizowanym oddziałem w Centrum Medycznym Rambam
• Koncentruje się na kompleksowej opiece nad pacjentem

Zastępca kierownika Oddziału Onkologii w Centrum Medycznym Rambam — Gil Bar-Sela zapewnia wieloletnie doświadczenie w kierowaniu opieką onkologiczną.

• Specjalizuje się w leczeniu i badaniach naukowych nad rakiem kości
• Pracuje w czołowym centrum medycznym w Izraelu
• Zapewnia kompleksową opiekę i prowadzenie pacjentów onkologicznych